The albendazole-treatment protocol excluded refugees with known cysticercosis or an unexplained seizure disorder due to the chance of adverse neurologic effects from a cysticidal agent. Because the overseas treatment recommendation was issued on May 1, 1999, refugees departing for the United States between January 1, 1993, april 30 and, 1999, were categorized as untreated, and refugees departing between May 1, 1999, and December 31, 2007, were categorized as albendazole-treated. Additional wellness screening data were not reported to the Minnesota Department of Health. Statistical Evaluation Prevalence ratios and 95 percent confidence intervals were calculated with the use of generalized-estimating-equation log-binomial regression versions with robust variance estimates to adjust for clustering according to family members.Adherence Parents of 467 of the kids reported having administered the analysis medication at least 75 percent of that time period, and parents of 517 kids reported having administered it at least 50 percent of that time period. Parents of 91 children in the prophylaxis group and of 76 children in the placebo group discontinued the analysis medication. No factor in reported adherence to the study-medication program was noted between your scholarly study groups. Recurrences of Febrile or Symptomatic Urinary Tract Infection During the trial, 111 kids got 171 recurrences of urinary tract infection .